[go: up one dir, main page]

MXPA05013869A - Metabolito de quetiapina. - Google Patents

Metabolito de quetiapina.

Info

Publication number
MXPA05013869A
MXPA05013869A MXPA05013869A MXPA05013869A MXPA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A MX PA05013869 A MXPA05013869 A MX PA05013869A
Authority
MX
Mexico
Prior art keywords
disorders
pharmaceutically acceptable
bipolar
symptoms
formula
Prior art date
Application number
MXPA05013869A
Other languages
English (en)
Inventor
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05013869A publication Critical patent/MXPA05013869A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un metodo para tratar la ansiedad, agitacion hostilidad, panico, trastornos alimentarios, sintomas afectivos, sintomas del estado de animo, sintomas psicoticos tanto negativos como positivos asociados comunmente con la esquizofrenia, demencia, ansiedad, depresion, trastornos del estado de animo, trastornos bipolares, mania bipolar, depresion bipolar, trastornos cognoscitivos y trastornos neurodegenerativos que comprende administrar una cantidad efectiva de la formula (I) o su sal farmaceuticamente aceptable. En otro aspecto de la invencion, se proporciona una composicion farmaceutica que comprende una cantidad efectiva de la formula (I) o su sal farmaceuticamente aceptable y al menos un portador o diluyente farmaceuticamente aceptable.
MXPA05013869A 2003-07-02 2004-06-28 Metabolito de quetiapina. MXPA05013869A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
MXPA05013869A true MXPA05013869A (es) 2006-02-28

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013869A MXPA05013869A (es) 2003-07-02 2004-06-28 Metabolito de quetiapina.

Country Status (20)

Country Link
US (1) US20050026900A1 (es)
EP (1) EP1644005B1 (es)
JP (1) JP2007516193A (es)
KR (1) KR20060082037A (es)
CN (1) CN1816339B (es)
AR (1) AR045004A1 (es)
AT (1) ATE477803T1 (es)
AU (1) AU2004253334A1 (es)
BR (1) BRPI0412127A (es)
CA (1) CA2531284A1 (es)
DE (1) DE602004028739D1 (es)
ES (1) ES2349091T3 (es)
IL (1) IL172616A0 (es)
IS (1) IS8283A (es)
MX (1) MXPA05013869A (es)
NO (1) NO20060556L (es)
RU (1) RU2005141060A (es)
TW (1) TW200509944A (es)
UY (1) UY28400A1 (es)
WO (1) WO2005002586A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
CA2550735A1 (en) 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
WO2006107948A2 (en) * 2005-04-04 2006-10-12 Acadia Pharmaceuticals Inc. Use of n-desmethylclozapine and related compounds as dopamine stabilizing agents
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
WO2007062339A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Liquid formulations
EP1951257A4 (en) * 2005-11-18 2008-11-05 Astrazeneca Ab CRYSTALLINE FORMS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
EP1951693A4 (en) * 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
WO2007062336A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Salt forms
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
EP2120957A4 (en) * 2006-12-20 2011-05-04 Astrazeneca Ab COMPOUNDS AND USES THEREOF
EP2120563A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USES
CN101616661A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
CN101641101A (zh) * 2007-03-22 2010-02-03 阿斯利康(瑞典)有限公司 治疗心境障碍的方法
EP2519101B1 (en) 2009-12-31 2015-08-19 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
HRP20190057T1 (hr) 2010-03-11 2019-03-22 Kempharm, Inc. Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5661184A (en) * 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
CN1741803A (zh) * 2003-01-23 2006-03-01 阿卡蒂亚药品公司 N－脱甲基氯氮平在治疗人神经精神疾病中的用途

Also Published As

Publication number Publication date
KR20060082037A (ko) 2006-07-14
DE602004028739D1 (de) 2010-09-30
ES2349091T3 (es) 2010-12-27
US20050026900A1 (en) 2005-02-03
NO20060556L (no) 2006-04-03
UY28400A1 (es) 2005-01-31
RU2005141060A (ru) 2006-07-27
EP1644005B1 (en) 2010-08-18
EP1644005A1 (en) 2006-04-12
TW200509944A (en) 2005-03-16
ATE477803T1 (de) 2010-09-15
WO2005002586A8 (en) 2006-02-09
CN1816339B (zh) 2010-12-15
CA2531284A1 (en) 2005-01-13
CN1816339A (zh) 2006-08-09
AR045004A1 (es) 2005-10-12
IL172616A0 (en) 2006-04-10
JP2007516193A (ja) 2007-06-21
AU2004253334A1 (en) 2005-01-13
BRPI0412127A (pt) 2006-08-15
WO2005002586A1 (en) 2005-01-13
IS8283A (is) 2006-02-01

Similar Documents

Publication Publication Date Title
MXPA05013869A (es) Metabolito de quetiapina.
Tandon et al. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
GEP20125405B (en) Amino-heterocyclic compounds
CY1111594T1 (el) Μεθοδοι για τη θεραπευτικη αντιμετωπιση της ψυχωσης και της σχιζοφρενειας με βαση πολυμορφισμους στο γονιδιο του cntf
WO2004019884A3 (en) Agents and methods for enhancing bone formation
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
JP2007516193A5 (es)
BRPI0512958A (pt) antagonistas de nk1
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
UA74337C2 (uk) Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії
DK1641454T3 (da) Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
TW200735878A (en) Pharmaceutical compositions
RU2006130687A (ru) Лечение психозов антипсихотическим агентом кветиапином
TW200507854A (en) Metabolite
JP2005517647A5 (es)
BR0009080A (pt) Método de tratamento da apnéia do sono
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
BR0111271A (pt) S-metil-dihidro-ziprasidona para tratamento de distúrbios psiquiátricos e oculares
SE9902938D0 (sv) Pharmaceutical compositions
ATE313547T1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten

Legal Events

Date Code Title Description
FA Abandonment or withdrawal